Portal de Periódicos da CAPES

A clinical evaluation of acetyl-digitoxin

1956; Elsevier BV; Volume: 51; Issue: 4 Linguagem: Inglês

10.1016/0002-8703(56)90105-3

1097-6744

R.B. Crouch, Milton R. Hejtmancik, George R. Herrmann,

Diabetes Treatment and Management

1. Acetyl-digitoxin by mouth was used in the therapy of 166 patients in congestive heart failure in the past eighteen months, and was demonstrated to be a well-tolerated and effective new digitalis glycoside. 2. The initial digitalizing dose can be given as a single dose or over a period of several days. The amount required must be adjusted for the patient, and usually varied from 1.6 to 2.0 mg., averaging 1.84 mg. In the single dose method, 1.6 to 1.8 mg. was well tolerated, but occasionally supplementary amounts were necessary for full digitalization. 3. Maintenance was also effective, and most patients could be maintained on 0.1 to 0.2 mg., the average being 0.15 mg. per day. 4. The excretion is slow, but appears somewhat more rapid than that of digitoxin. Toxic effects disappeared generally in one to three days, but the total elimination of drug effect from patients in atrial fibrillation required thirteen to seventeen days. 5. Toxic effects were generally deliberately attained, and consisted of gastrointestinal symptoms in the majority of patients. There were no serious arrhythmias and no fatalities which could be ascribed to the drug. 6. The therapeutic range was similar to that of the other glycosides. 7. It appears that acetyl-digitoxin will attain merit as a long-acting glycoside which is well tolerated even in single digitalizing dosage by mouth and which is effective therapeutically. It has the advantage over digitoxin of some-what more rapid dissipation, and toxic effects are usually gastrointestinal symptoms instead of potentially dangerous arrhythmias. 1. In le curso del passate 18 menses, acetyl-digitoxina per via oral esseva usate in le therapia de 166 patientes in congestive disfallimento cardiac. Illo se provava un ben-tolerate e efficace nove glycosido digital. 2. Le dosage digitalisante initial pote esser administrate in un dose unic o distribuite super un periodo de plure dies. Le quantitate requirite debe esser adjustate secundo le patiente individual. In nostre casos illo variava usualmente ab 1,6 a 2,0 mg (con un valor median de 1,84 mg). In administrationes a dose unic, 1,6 a 1,8 mg esseva ben tolerate, sed in certe casos quantitates additional esseva requirite pro obtener digitalisation complete. 3. Le droga esseva etiam efficace como agente de mantenentia. In le majoritate del casos, le mantenentia del patientes esseva effectuabile per 0,1 a 0,2 mg per die (con un valor median de 0,15 mg). 4. Le excretion es lente sed se manifesta alique plus rapidemente que le excretion de digitoxina. Effectos toxic dispareva generalmente in un a tres dies, sed le complete elimination del effectos drogal ab patientes in fibrillation atrial requireva 13 a 17 dies. 5. In le majoritate del patientes le effectos toxic consisteva de symptomas gastro-intestinal. Pro rationes investigative, iste effectos esseva generalmente permittite sin effortio a evitar los. Il habeva nulle sever arrhythmias, e nulle morte esseva attribuibile al administration del droga. 6. In su dimension therapeutic le droga esseva simile a altere glycosidos. 7. Il es permissibile asserer que acetyl-digitoxina va provar su merito como glycosido a longe durantia—un glycosido que es ben tolerate mesmo in unic dosages digitalisante per via oral e que es efficace therapeuticamente. In comparation con digitoxina illo ha le avantage de un alique plus rapide dissipation. Su effectos toxic es normalmente symptomas gastro-intestinal in loco de potentialmente periculose arrhythmias.